MRVI General Counsel sells 50,000 shares

MARAVAI LIFESCIENCES HOLDINGS, INC.

Rhea-AI Filing Summary

MARAVAI LIFESCIENCES HOLDINGS, INC. General Counsel Kurt Oreshack reported open-market sales of Class A Common Stock. He sold 25,000 shares on June 9, 2026 at $5.06 per share and 25,000 shares on June 10, 2026 at $5.10 per share. These transactions were effected under a pre-arranged Rule 10b5-1 trading plan. Following the sales, he directly holds 335,767 shares of Maravai Lifesciences stock.

Insider Trade Summary 10b5-1

Net Seller: 50,000 shares

Net Sell 2 txns

Insider ORESHACK KURT

Role General Counsel

Sold 50,000 shs ($254K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	25,000	$5.10	$127K
Sale	Class A Common Stock	25,000	$5.06	$126K

Holdings After Transaction: Class A Common Stock — 335,767 shares (Direct)

Footnotes (1)

1. F1. The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

Key Figures

Shares sold June 9, 2026: 25,000 shares at $5.06 Shares sold June 10, 2026: 25,000 shares at $5.10 Total shares sold: 50,000 shares +2 more

5 metrics

Shares sold June 9, 2026 25,000 shares at $5.06 Open-market sale of Class A Common Stock

Shares sold June 10, 2026 25,000 shares at $5.10 Open-market sale of Class A Common Stock

Total shares sold 50,000 shares Two open-market sales reported in Form 4

Shares held after transactions 335,767 shares Direct ownership after June 10, 2026 sale

Rule 10b5-1 plan adoption date March 10, 2026 Plan governing reported sales

Key Terms

Rule 10b5-1 trading plan, Class A Common Stock, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Class A Common Stock financial

"The transactions involve non-derivative Class A Common Stock in open-market sales."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

open-market sale financial

"Each transaction is described as an open-market sale of Class A Common Stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The insider activity is reported in a Form 4 filing for Maravai Lifesciences."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MRVI General Counsel Kurt Oreshack report?

Kurt Oreshack reported selling a total of 50,000 shares of Maravai Lifesciences Class A Common Stock in open-market transactions, split evenly over two days at prices slightly above $5.00 per share.

On what dates did MRVI’s General Counsel sell shares and at what prices?

He sold 25,000 shares on June 9, 2026 at $5.06 per share and another 25,000 shares on June 10, 2026 at $5.10 per share in open-market sales.

How many MRVI shares does Kurt Oreshack hold after these Form 4 sales?

After the reported transactions, Kurt Oreshack directly holds 335,767 shares of Maravai Lifesciences Class A Common Stock, as shown in the post-transaction ownership column of the Form 4 filing.

Were the MRVI insider stock sales made under a Rule 10b5-1 plan?

Yes. The filing states the reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2026, indicating the trades were pre-arranged.

What is the role of the insider selling MRVI stock in this Form 4?

The reporting person, Kurt Oreshack, is identified as an officer of Maravai Lifesciences with the title General Counsel. The transactions involve his directly owned Class A Common Stock holdings.

What type of transaction is reported in the MRVI Form 4 filing?

The Form 4 lists two open-market sales of non-derivative Class A Common Stock, coded as “S” for sale, with both transactions described as sales in open market or private transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 05:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ORESHACK KURT

(Last) (First) (Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIRCLE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/09/2026		S		25,000(1)	D	$5.06	360,767	D
Class A Common Stock	06/10/2026		S		25,000(1)	D	$5.1	335,767	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

Remarks:

	/s/ Kurt Oreshack	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)